Expertise Partner

We share your passion for science. Promega is committed to excellence in technologies to assess key processes in PROTAC-induced protein degradation: compound binding and permeability, ternary complex formation, ubiquitination, and trafficking to proteasome. Assay live cells in kinetic mode to determine target protein degradation rates, DC50 potency values, and recovery profiles. Let’s collaborate.

Chemical Computing Group

Chemical Computing Group

Program Partner

CCG (Chemical Computing Group) is a leading supplier of software solutions for life sciences. With a proven track record in scientific innovation, CCG provides state-of-the-art applications in drug discovery to pharmaceutical, biotechnology and academic researchers. CCG headquarters are in Montreal (Canada), with support offices in North America, Europe and Asia.


Ubiquigent Ltd

Innovation Partner

Ubiquigent Ltd is a unique enabler of ubiquitin system and protein degradation-based drug discovery.  Our commercial models include FFS and FTE access and features our Collaborative Drug Discovery programme.  We provide access to the necessary expertise, Drug Discovery Services, Chemistry (novel deubiquitylase – DUB – enzyme-focussed libraries) and high quality Research Tools required to support our commercial and academic partners in pursuing ubiquitin system-focused drug discovery and protein degradation programmes, and in undertaking basic research.






Exhibition Partner

Biodesy has developed a unique technology to detect structural changes in biological molecules, based on a phenomenon called second-harmonic generation (SHG), with applications in drug discovery and structural biology. Our sensitive, mass-independent platform can detect even weak affinity interactions, enabling a variety of approaches for challenging targets, from RNA to large protein complexes. In addition to our flagship product, the Delta™, we provide access to the technology through services to accomplish defined deliverables.



Exhibition Partner

Bio-Techne brings together some of the most referenced brands in life science to provide innovative tools for Targeted Protein Degradation. Boston Biochem are world leaders in ubiquitin-proteasome system-related products, Tocris Bioscience are market leaders for research tool Degraders and Degrader building blocks while ProteinSimple provide automated platforms for detecting and quantifying protein degradation via Western Blot.
Together we are Bio-Techne. Find out how we can help you achieve your research goals.



Event Partner

BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs focusing on orally available small molecules for the treatment of cancers and inflammatory diseases.  Our lead molecule targets Acute Myeloid Leukemia (in clinic Q2 2019) and our lead Protein Homeostatic Modulator (PHM™) will be in the clinic Q3 2020 for hematological malignancies.

Sponsorship opportunities